Compare iShares MSCI ACWI ETF (ACWI) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Cytokinetics Inc — how do they compare? iShares MSCI ACWI ETF trades at $161.58, while Cytokinetics Inc trades at $76.73 (market cap $10.63B). The key difference: iShares MSCI ACWI ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals.
| ACWI | CYTK | |
|---|---|---|
52-Week High | $161.44 | $87.26 |
52-Week Low | $132.04 | $34.31 |
Market Cap | — | $10.63B |
Sector | — | Technology |
Enterprise Value | — | $10.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $161.72, up 0.38% today, with a bullish technical signal from moving averages and strong trend momentum indicated by ADX. The ETF's forward P/E of 15.5x, as of Seeking Alpha on 2026-07-07, suggests reasonable valuation amid robust earnings growth, with Information Technology now comprising 32% of holdings. A dividend of $1.01 is scheduled for June 2026.
Outlook remains positive due to strong EPS growth and institutional interest, though overbought RSI levels near 74.95 signal caution. Risks include market volatility from AI-driven inflows and potential sector concentration, but analyst sentiment supports a buy rating for long-term global equity exposure.
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
